Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/23/2026

1. GOOGL
2. TXN
3. NOW
4. TSLA
5. GOOG
6. IBM
7. KNX
8. CSX
9. LVS
10. INTC

Go back to Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study
(NASDAQ: ERNA) Delayed: 4.45 --0 (-0%)
Previous Close $4.45    52 Week High $ 
Open $4.45    52 Week Low $ 
Day High $4.45    P/E N/A 
Day Low $4.45    EPS $ 
Volume 4,169       

(NASDAQ: ERNA) Delayed: 4.45 --0 (-0%)
Previous Close $4.45    52 Week High $ 
Open $4.45    52 Week Low $ 
Day High $4.45    P/E N/A 
Day Low $4.45    EPS $ 
Volume 4,169